Abstracts Archive - Page 834 of 2425 - ACR Meeting Abstracts

Abstract Number: 1134 • 2019 ACR/ARP Annual Meeting
Medicaid Spending (2013-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Deepan Dalal¹, Tingting Zhang ² and Theresa Shireman ², ¹Brown University, Riverside, RI, ²Brown University, Providence, RI
Background/Purpose: The management of rheumatoid arthritis (RA) and other conditions have improved tremendously since the introduction of biologic disease modifying agents (DMARDs). However, these agents…
Abstract Number: 1135 • 2019 ACR/ARP Annual Meeting
Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial
Elena Myasoedova¹, Cynthia Crowson ², Rachel Giblon ¹, Kathleen McCarthy-Fruin ¹, Daniel Schaffer ¹, Kerry Wright ¹, Eric Matteson ³ and John Davis ¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, ³Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester
Background/Purpose: Flares in rheumatoid arthritis (RA) are common. The shortage of readily available specialized care may hinder early detection and timely management of RA flares.…
Abstract Number: 1136 • 2019 ACR/ARP Annual Meeting
Improving Access in an Academic Rheumatology Department by Reducing the No Show Rate
Richard Zamore¹, ¹Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: No shows are a widespread problem across medical practices, and lead to negative consequences for patients and providers (Mendel 2017). The rheumatology division at…
Abstract Number: 1137 • 2019 ACR/ARP Annual Meeting
Predictors of Health-Related Quality of Life in Patients with Musculoskeletal Diseases: A Longitudinal Analysis from an Electronic Health Record Database
Luis Rodríguez-Rodríguez¹, Alfredo Madrid García ¹, Judit Font Urgelles ², Leticia León ³, Dalifer Freites Nuñez ⁴, Cristina Lajas ⁵, Esperanza Pato Cour ⁵, Juan Angel Jover Jover ⁵, Benjamín Fernández Gutiérrez ⁶ and lydia Abasolo Alcazar ⁵, ¹Fundación para la Investigación Biomedica, Madrid, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain, ³Fundación para la Investigación Biomedica, Madrid, Madrid, Spain, ⁴Hospital Clínico San Carlos, MADRID, Spain, ⁵HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ⁶Hospital Clínico San Carlos, Madrid
Background/Purpose: Musculoskeletal diseases (MSKs) are the major cause of disability, affecting the patient's daily activities as well as their Quality of Life (QoL). Our objective…
Abstract Number: 1138 • 2019 ACR/ARP Annual Meeting
Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices
Colin Edgerton¹, Janna Radtchenko ² and V. Michael Holers ³, ¹Articularis Healthcare, Charleston, ²Trio Health, La Jolla, CA, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver
Background/Purpose: RA is an autoimmune disease affecting over 1.5 million Americans. Biologic disease-modifying antirheumatic drugs (bDMARDs) expanded treatment choices for RA patients (pts) in the…
Abstract Number: 1139 • 2019 ACR/ARP Annual Meeting
Lifetime Direct Medical and Indirect Cost of Knee Osteoarthritis: Impact of Pain and Structural Severity
Elizabeth Stanley¹, James Sullivan ², Jamie Huizinga ¹, Jamie Collins ³, Jeffrey Katz ⁴ and Elena Losina ⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital and Harvard Medical School, Boston, ⁴Brigham and Women's Hospital/Harvard Medical School, Boston, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Symptomatic knee OA is a debilitating condition that affects 14 million adults in the US. We estimated the variability of lifetime OA-related direct and…
Abstract Number: 1140 • 2019 ACR/ARP Annual Meeting
The Socioeconomic, Gender, Urban-rural, and Regional Disparities in the Risk of Acute Myocardial Infarction Among RA Patients
Yufei Zheng¹, Hui Xie ², J. Antonio Avina-Zubieta ³, Kia Yazdani ⁴, John Esdaile ⁵ and Diane Lacaille ⁶, ¹Arthritis Research Canada, Richmond, BC, Canada, ²Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Richmond, ⁵Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁶Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: To assess socioeconomic (SES), gender, urban-rural, and regional disparities in the risk of acute myocardial infarction (MI) among rheumatoid arthritis patients.Methods: We conducted a…
Abstract Number: 1141 • 2019 ACR/ARP Annual Meeting
Racial Disparities in Lupus Medication Adherence
Kai Sun¹, Amanda Eudy ¹, Jennifer Rogers ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, Rebecca Sadun ¹ and Megan Clowse ¹, ¹Duke University, Durham
Background/Purpose: Medication non-adherence is common among SLE patients and is disproportionately more frequent in underrepresented racial minorities. We examined adherence gaps between minority and Caucasian…
Abstract Number: 1142 • 2019 ACR/ARP Annual Meeting
Barriers and Facilitators of Medication Adherence Among Minority SLE Patients: A Qualitative Study
Kai Sun¹, Carrie Dombeck ¹, Teresa Swezey ¹, Amy Corneli ¹, Amanda Eudy ¹, Rebecca Sadun ¹, Jennifer Rogers ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹ and Megan Clowse ¹, ¹Duke University, Durham
Background/Purpose: SLE disproportionately affects underrepresented racial minorities, groups that often have lower rates of medication adherence. This study aimed to explore barriers and facilitators of…
Abstract Number: 1143 • 2019 ACR/ARP Annual Meeting
Racial Disparities in Factors Associated with SLICC Damage Score Among Patients with SLE
Kai Sun¹, Amanda Eudy ¹, Jennifer Rogers ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, Rebecca Sadun ¹ and Megan Clowse ¹, ¹Duke University, Durham
Background/Purpose: Significant racial disparities exist in SLE outcomes. Few studies have examined modifiable factors intrinsic to physician/patient encounters that may contribute to such disparities. We…
Abstract Number: 1144 • 2019 ACR/ARP Annual Meeting
Understanding Clinical Trials Participation Among Individuals of African Descent with Lupus Through the Lens of Critical Race Theory: A Qualitative Analysis
Candace Feldman¹, Jessica Williams ¹, Courtnie Phillip ¹, Corine Sinnette ¹, Karen Mancera-Cuevas ², Patricia Canessa ³, Gina Curry ⁴, Maryann Mason ² and Rosalind Ramsey-Goldman ², ¹Brigham and Women's Hospital, Boston, MA, ²Northwestern University, Chicago, IL, ³IPHA, Chicago, IL, ⁴University of Chicago, Chicago, IL
Background/Purpose: Despite a disproportionate burden of lupus and poorer outcomes among individuals of African descent (hereafter “black”) compared to white individuals, black individuals are underrepresented…
Abstract Number: 1145 • 2019 ACR/ARP Annual Meeting
The Representation of Skin Tones in Images of Patients with Lupus Erythematosus
Amaad Rana¹, Abbey Witt ¹, Heather Jones ¹, Muithi Mwanthi ¹ and Lisa Zickuhr ¹, ¹Washington University School of Medicine, Saint Louis
Background/Purpose: Racial disparities exist in healthcare. Research shows that the disproportionate representation of race in educational materials contributes to this disparity. Race is a known…
Abstract Number: 1146 • 2019 ACR/ARP Annual Meeting
Therapy of Lupus Nephritis with Mycophenolate Mofetil in Routine Clinical Practice: Response Rates and Role of Ethnicity
Prathima Anandi ¹, Alyson Dickson ², Vivian Kawai ², C. Michael Stein ² and Cecilia Chung³, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN
Background/Purpose: Randomized clinical trials have reported that 56-68% of patients with lupus nephritis treated with mycophenolate mofetil (MMF) respond to therapy, and a randomized clinical…
Abstract Number: 1147 • 2019 ACR/ARP Annual Meeting
Poverty and Systemic Lupus International Collaborating Clinics Damage Index (SDI) Are Significant Risk Factors for Hospitalization in SLE Patients
Allen Anandarajah¹, Caroline Thirukumaran ¹, Kelly callahan ¹, Jennifer Anolik ¹ and Christopher Ritchlin ², ¹University of Rochester Medical Center, Rochester, NY, ²Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with a high rate of hospitalizations and is the sixth highest reason for 30-day readmissions among all medical…
Abstract Number: 1148 • 2019 ACR/ARP Annual Meeting
Examining Five Year Lupus Retention in Care in an Academic Cohort
Christie Bartels¹ and Maria Schletzbaum ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: SLE often causes silent damage, making routine clinic and lab monitoring critical for detecting new manifestations or flares. The 2012 ACR nephritis guidelines recommended…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].